FOX CHASE CHEMICAL DIVERSITY CENTER INC.
Stapled alpha-helical peptide antiviral therapeutic targeting HSV-1 processivity factors for treatment of acyclovir-resistant herpes keratitis
- Sector
- Biotech
- Headquarters
- Doylestown, PA
- Total capital
- $52.2M
- Federal grants
- $51.9M
- 67 awards · 2014–2025
- Rank in peer group#15 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $307K
- 1 award · Health and Human S
- Rank in Biotech#259 of 4373
- Granted patents
- 0
- 12 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum$967K
- Federal grantHealth and Human S · Phase II · Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle$1M
- Federal contractHealth and Human S · SBIR Topic 134$307K
- Federal grantHealth and Human S · Phase II · Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum$1M
- Federal grantHealth and Human S · Phase II · Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis$976K
- Federal grantHealth and Human S · Phase II · Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle$1M
- Federal grantHealth and Human S · Phase I · Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),$292K
Show 61 earlier federal awards
- Federal grantHealth and Human S · Phase I · Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens$292K
- Federal grantHealth and Human S · Phase II · Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis$990K
- Federal grantHealth and Human S · Phase II · Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle$1.1M
- Federal grantHealth and Human S · Phase II · Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$1M
- Federal grantHealth and Human S · Phase I · Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),$599K
- Federal grantHealth and Human S · Phase I · Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),$307K
- Federal grantHealth and Human S · Phase I · Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens$307K
- Federal grantHealth and Human S · Phase II · Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis$2M
- Federal grantHealth and Human S · Phase II · Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis$1.1M
- Federal grantHealth and Human S · Phase II · Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$1M
- Federal grantHealth and Human S · Phase I · Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum$300K
- Federal grantHealth and Human S · Phase I · Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle$300K
- Federal grantHealth and Human S · Phase I · PROTACS Against Nef as a Functional Cure for HIV Infection$298K
- Federal grantHealth and Human S · Phase II · Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT$1.0M
- Federal grantHealth and Human S · Phase I · Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum$307K
- Federal grantHealth and Human S · Phase I · Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum$607K
- Federal grantHealth and Human S · Phase II · Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$3M
- Federal grantHealth and Human S · Phase II · Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$1M
- Federal grantHealth and Human S · Phase II · Riluzole Prodrugs for Melanoma and ALS$1M
- Federal grantHealth and Human S · Phase I · Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle$300K
- Federal grantHealth and Human S · Phase I · Soft LXR Agonists for Idiopathic Pulmonary Fibrosis$307K
- Federal grantHealth and Human S · Phase I · PROTACS Against Nef as a Functional Cure for HIV Infection$598K
- Federal grantHealth and Human S · Phase I · PROTACS Against Nef as a Functional Cure for HIV Infection$300K
- Federal grantHealth and Human S · Phase II · Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT$996K
- Federal grantHealth and Human S · Phase I · Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis$309K
- Federal grantHealth and Human S · Phase I · Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis$309K
- Federal grantHealth and Human S · Phase II · Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT$1.0M
- Federal grantHealth and Human S · Phase II · Riluzole Prodrugs for Melanoma and ALS$1M
- Federal grantHealth and Human S · Phase I · Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$297K
- Federal grantHealth and Human S · Phase I · Discovering a Small Molecule that Targets the KSHV Processivity Factor for Treating Oral and Systemic Kaposi Sarcoma$300K
- Federal grantHealth and Human S · Phase I · Discovering a Small Molecule that Targets the KSHV Processivity Factor for Treating Oral and Systemic Kaposi Sarcoma$300K
- Federal grantHealth and Human S · Phase I · Soft LXR Agonists for the Treatment of Idiopathic Pulmonary Fibrosis$300K
- Federal grantHealth and Human S · Phase II · Riluzole Prodrugs for Melanoma and ALS$1M
- Federal grantHealth and Human S · Phase I · Trigriluzole for the Treatment of Cocaine Addiction$300K
- Federal grantHealth and Human S · Phase I · Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$597K
- Federal grantHealth and Human S · Phase I · Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$300K
- Federal grantHealth and Human S · Phase II · PET Imaging Agents for the in vivo Detection of TDP-43$754K
- Federal grantHealth and Human S · Phase II · Development Of Topical Antiviral Agents For Treating Molluscum Contagiosum$999K
- Federal grantHealth and Human S · Phase II · PET Imaging Agents for the in vivo Detection of TDP-43$745K
- Federal grantHealth and Human S · Phase II · Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS$991K
- Federal grantHealth and Human S · Phase II · Small Molecule Antagonists Of PF4 For The Treatment And Prevention Of Hit$962K
- Federal grantHealth and Human S · Phase I · Inhibitors of Hydrogen Sulfide Metabolism as a Novel Treatment for Heart Failure$300K
- Federal grantHealth and Human S · Phase I · Inhibitors of Hydrogen Sulfide Metabolism as a Novel Treatment for Heart Failure$300K
- Federal grantHealth and Human S · Phase II · Development Of Topical Antiviral Agents For Treating Molluscum Contagiosum$1M
- Federal grantHealth and Human S · Phase I · Inhibitors Of The PHD2 Zinc Finger To Treat Anemia$300K
- Federal grantHealth and Human S · Phase I · Development Of A Novel Antiviral To Treat And Prevent Acyclovir Resistance In Human Ocular Herpes Keratitis$300K
- Federal grantHealth and Human S · Phase I · Development Of A Novel Antiviral To Treat And Prevent Acyclovir Resistance In Human Ocular Herpes Keratitis$300K
- Federal grantHealth and Human S · Phase II · Small Molecule Inhibitors of HIV Nef Virulence Factor for Treatment of HIV AIDS$2M
- Federal grantHealth and Human S · Phase II · Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS$1M
- Federal grantHealth and Human S · Phase II · Small Molecule Antagonists Of PF4 For The Treatment And Prevention Of Hit$980K
- Federal grantHealth and Human S · Phase II · Development Of Topical Antiviral Agents For Treating Molluscum Contagiosum$3M
- Federal grantHealth and Human S · Phase I · Development Of Drugs That Target The M2 Proton Channel From Influenza A Virus$40K
- Federal grantHealth and Human S · Phase II · Development Of Topical Antiviral Agents For Treating Molluscum Contagiosum$1M
- Federal grantHealth and Human S · Phase II · Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses$1.2M
- Federal grantHealth and Human S · Phase II · A Novel Therapeutic for Invasive Candidiasis$750K
- Federal grantHealth and Human S · Phase I · Pregnane X Receptor (PXR) Antagonists for Non-Alcoholic Fatty Liver Disease$300K
- Federal grantHealth and Human S · Phase I · Development Of Small Molecule Therapeutics Against Rna Viruses$300K
- Federal grantHealth and Human S · Phase I · Development Of Drugs That Target The M2 Proton Channel From Influenza A Virus$300K
- Federal grantHealth and Human S · Phase I · Development Of Small Molecule Therapeutics Against Rna Viruses$300K
- Federal grantHealth and Human S · Phase II · Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses$2.3M
- Federal grantHealth and Human S · Phase II · Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses$1.1M
Federal awards are summed by year (68 awards); hover a bar for the split. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#15 · top 3%
- Linked publications#11 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 12- PendingCompounds, Compositions, And Methods For Cell-specific PharmacologyUSPTOApplication 18866835
- PendingSmall Molecules That Bind To TDP-43 For The Treatment Of Als And Related DisordersUSPTOApplication 18546285
- PendingMolecules That Bind To TDP-43 For The Treatment Of Amyotrophic Lateral Sclerosis And Related DisordersUSPTOApplication 17635421
Show all 12 patent records
- Compounds, Compositions, And Methods For Cell-specific PharmacologyJul 3, 2025 · Application 18866835Pending
- Small Molecules That Bind To TDP-43 For The Treatment Of Als And Related DisordersMay 9, 2024 · Application 18546285Pending
- Molecules That Bind To TDP-43 For The Treatment Of Amyotrophic Lateral Sclerosis And Related DisordersDec 8, 2022 · Application 17635421Pending
- Novel Bis-amide Containing Compounds Exhibiting Antifungal Activity And Their Method Of UseApplication PCTUS2022036746Pending
- Small Molecule Antagonists Of PF4Application PCTUS2022021370Pending
- Novel Heteroaromatic Compounds Exhibiting Antifungal Activity And Their Method Of UseApplication PCTUS2022019220Pending
- Targeted Degraders Of HIV-1 Nef For The Treatment Of Hiv DiseaseApplication 63522932Pending
- Novel Heteroaromatic Compounds Exhibiting Antifungal Activity And Their Method Of UseApplication PCTUS2021035568Pending
- Pro-drugs Of Riluzole And Their Method Of Use For The Treatment Of Amyotrophic Lateral SclerosisApplication PCTUS2013047315Pending
- Novel Fluorinated Sulfamides Exhibiting Neuroprotective Action And Their Method Of UseApplication PCTUS2011061341Pending
- Novel Sulfamides Exhibiting Neuroprotective Action And Methods For Use ThereofApplication PCTUS2011023536Pending
- Targeted Degraders Of HIV-1 Nef For The Treatment Of Hiv DiseaseApplication 19492022Pending
Recent research by its founders
- A stapled viral peptide blocks HSV-2 from infecting human cervical cells20260 cites
- Constraining regulatory domain dynamics of the Src kinase Fgr increases ATP-site inhibitor sensitivity and impairs bone marrow engraftment20260 cites
- Design and Optimization of Benzoic Acid Inhibitors Targeting the EBNA1 DNA-Binding Interface20260 cites
Related companies, and why
- Ovation.io, Inc.Similar federal contract value in Biotech · $329K in contracts
- Beta Hatch Inc.Similar federal contract value in Biotech · $324K in contracts
- Celltheon CorpSimilar federal contract value in Biotech · $322K in contracts
- VENTRIA BIOSCIENCESimilar federal contract value in Biotech · $305K in contracts
- MIRECULE INCSimilar federal contract value in Biotech · $305K in contracts
- AMYRIS, INC.Similar federal contract value in Biotech · $303K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .